For T0901317 experiments, mice were injected intraperitoneally with either vehicle (10%DMSO in 90% corn oil) or T0901317 (MedChem Express, HY-10626) at a dose of either 16.9 mg/kg or 50 mg/kg dose for either 4 days (1720) days post AAV-TBG-Cre treatment) or 14 days (720) days post AAV-TBG-Cre treatment)
See the related Commentary at Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?.
Clearly, the added benefits are welcome news, he explained
And according to Healthline , the medication remains costly
If deficiencies are detected, targeted supplementation under medical supervision is appropriate
Key Takeaways Loose skin is a structural issue: Significant weight loss stretches the physical matrix of the skin, which no cream can shrink back down